Gian Lifecare Ltd
Incorporated in 2018, Gian Lifecare Ltd is in the business of independent diagnostic/pathological laboratories[1]
- Market Cap ₹ 14.9 Cr.
- Current Price ₹ 14.4
- High / Low ₹ 24.4 / 12.1
- Stock P/E
- Book Value ₹ 18.6
- Dividend Yield 0.00 %
- ROCE 2.23 %
- ROE -0.21 %
- Face Value ₹ 10.0
Pros
- Stock is trading at 0.78 times its book value
Cons
- Company has low interest coverage ratio.
- Promoter holding is low: 32.1%
- Company has a low return on equity of 10.1% over last 3 years.
- Promoters have pledged or encumbered 61.2% of their holding.
- Company has high debtors of 335 days.
- Promoter holding has decreased over last 3 years: -32.9%
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Healthcare Services Healthcare Service Provider
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
---|---|---|---|---|---|
15.45 | 11.41 | 12.78 | 6.63 | 5.52 | |
9.39 | 9.56 | 6.63 | 5.71 | 4.71 | |
Operating Profit | 6.06 | 1.85 | 6.15 | 0.92 | 0.81 |
OPM % | 39.22% | 16.21% | 48.12% | 13.88% | 14.67% |
0.51 | 0.69 | 0.67 | 0.26 | 0.24 | |
Interest | 0.39 | 0.45 | 0.54 | 0.51 | 0.46 |
Depreciation | 0.33 | 0.50 | 0.53 | 0.63 | 0.62 |
Profit before tax | 5.85 | 1.59 | 5.75 | 0.04 | -0.03 |
Tax % | 25.30% | 33.33% | 27.65% | 200.00% | |
4.37 | 1.06 | 4.15 | -0.04 | -0.08 | |
EPS in Rs | 4.23 | 1.02 | 4.01 | -0.04 | -0.07 |
Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% |
Compounded Sales Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | -25% |
TTM: | -56% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | -102% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | 3% |
3 Years: | -22% |
1 Year: | -35% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 10% |
Last Year: | 0% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|
Equity Capital | 10.34 | 10.34 | 10.34 | 10.34 |
Reserves | 3.69 | 4.78 | 8.93 | 8.89 |
2.03 | 4.57 | 4.88 | 5.85 | |
7.00 | 8.56 | 8.48 | 10.85 | |
Total Liabilities | 23.06 | 28.25 | 32.63 | 35.93 |
3.50 | 4.62 | 5.07 | 4.59 | |
CWIP | 0.12 | 0.14 | 0.14 | 0.00 |
Investments | 0.00 | 0.00 | 0.00 | 0.00 |
19.44 | 23.49 | 27.42 | 31.34 | |
Total Assets | 23.06 | 28.25 | 32.63 | 35.93 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|
5.79 | 2.22 | 0.70 | 0.27 | |
-4.12 | -0.94 | -0.32 | 0.25 | |
0.67 | -0.37 | -0.16 | 0.45 | |
Net Cash Flow | 2.34 | 0.91 | 0.22 | 0.97 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|
Debtor Days | 42.05 | 103.97 | 137.37 | 335.27 |
Inventory Days | 188.58 | |||
Days Payable | 1,134.54 | |||
Cash Conversion Cycle | 42.05 | 103.97 | 137.37 | -610.69 |
Working Capital Days | -31.66 | -161.55 | -81.40 | -67.71 |
ROCE % | 11.41% | 28.70% | 2.23% |
Documents
Announcements
-
Results For Quarter Ended June 30, 2025
2d - Board approved FY25 and Q1 June 30, 2025 results; auditor flagged ~₹693.86L cash vs ~₹421.99L dues.
- Results For Financial Year 01/04/2024-31/03/2025 2d
-
Board Meeting Outcome for Outcome Of Board Meeting Held On Thursday, August 14, 2025
2d - Board approved FY2025 results; auditor qualified over unspent IPO and Rs.694.55l cash vs Rs.421.99l statutory dues.
-
Update on board meeting
7 Aug - Board meetings on Aug 14 to approve audited and unaudited financial results for FY25 and Q1 FY26.
-
Board Meeting Intimation for Intimation Of Board Meeting To Consider And Approve Audited Standalone And Consolidated Financial Results Of The Company For The Quarter/ Half Year And Year Ended 31St March, 2025
7 Aug - Board meeting on Aug 14, 2025, to approve audited financial results for year ended March 31, 2025.
Annual reports
Concalls
-
Nov 2021TranscriptNotesPPT
Business Overview:[1]
GLL provides diagnostic and healthcare testing services across Kanpur and nearby cities. It offers patient diagnosis, prevention, and wellness services to individuals and healthcare providers. The company is expanding its network with new diagnostic labs nationwide. In addition to its major lab in Kanpur, its Lucknow lab became fully operational in FY23.